"Braking" the Cycle of Resistance in Endocrine Therapy for Breast Cancer
- PMID: 26202949
- DOI: 10.1158/1078-0432.CCR-15-1146
"Braking" the Cycle of Resistance in Endocrine Therapy for Breast Cancer
Abstract
Endocrine resistance leads to recurrence and death from breast cancer. Animal models of endocrine resistance enable preclinical identification of efficacious therapeutic combinations and further our understanding of resistance. This strategy provides new insights into optimally targeting interactions between estrogen receptor (ESR-1) activity and the cell cycle by CDK4/6 inhibitors. See related article by Wardell et al., p. 5121.
©2015 American Association for Cancer Research.
Comment on
-
Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy-Resistant Breast Cancer.Clin Cancer Res. 2015 Nov 15;21(22):5121-5130. doi: 10.1158/1078-0432.CCR-15-0360. Epub 2015 May 19. Clin Cancer Res. 2015. PMID: 25991817 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous